NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions." In cancer patients, BRAF-targeting precision ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Recurrent IRTC invading the upper aerodigestive tract remains a formidable clinical challenge. Management typically involves tracheal resection or laryngectomy, often with sacrifice of the recurrent ...